CB 839

Drug Profile

CB 839

Alternative Names: CB839

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Calithera Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Renal cell carcinoma
  • Phase I/II Malignant melanoma; Non-small cell lung cancer
  • Phase I Haematological malignancies; Leukaemia; Solid tumours

Most Recent Events

  • 07 Aug 2017 Phase-II clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada, Europe (PO) (NCT03163667)
  • 07 Aug 2017 Calithera Biosciences initiates enrolment in a phase II trial for Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT03163667)
  • 07 Jun 2017 CB 839 receives Fast Track designation for Renal cell carcinoma [PO,Capsule] (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top